Manufacturing The strategic investments expanding CDMO capabilities for HPAPIs and ADCs Pharmaceutical TechnologyDemand for HPAPIs and ADCs is accelerating, prompting CDMOs to invest to strengthen manufacturing capabilities for oncology.Read full story pharminent April 29, 2026 (Last updated: April 29, 2026) Pharmaceutical Technology Demand for HPAPIs and ADCs is accelerating, prompting CDMOs to invest to strengthen manufacturing capabilities for oncology. Read full story Post navigation Previous: Novartis’ Q1 sales miss hints at industry’s utilisation of M&A remediesNext: Eli Lilly bets on recombinases in $2.25bn Profluent R&D pact Related Stories Manufacturing BMS banks on Texas for $2.3bn multi-modal manufacturing facility pharminent August 11, 2026 Manufacturing AsymBio to secure $184m to support growth in biologics manufacturing pharminent August 5, 2026 Manufacturing Lilly and Resilience invest $750M in diabetes and obesity drug device supply pharminent July 31, 2026
